Digital Media briefs

Share this article:
AstraZeneca launched a corporate blog—AZ Health Connections—à la JNJ BTW and GlaxoSmithKline's More Than Medicine. The blog is edited by Earl Whipple, a senior director in the company's corporate communications group. In his inaugural blog post, Whipple said the company wants the blog to function as “a forum where you can interact with AstraZeneca US, while we work and innovate on the front lines of healthcare.” The blog has not discussed specific AZ products.

Everyday Health added to its portfolio of sites via strategic partnership. The move reflects a greater focus on animal health brands at pharmaceutical companies, as well as the recent launch of WebMD Healthy Pets. launched in 2008, and was deemed the “WebMD for Pets” by a syndicated TechCrunch reporter.

Diabetes Mine, an online patient community, partnered with to launch DiabetesMine Health Plans. The health plans provide consumers with individually-customized suggestions on how to manage diabetes., a personalized health management site, was founded by Adam Bosworth, formerly the head of Google Health.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?